New Set of External Quality Assessment Programs Launched
By LabMedica International staff writers Posted on 20 Dec 2015 |
A set of eight new RIQAS external quality assessment (EQA; also referred to as proficiency testing (PT)) programs have been launched to provide clinical laboratories with the ability to review calibration issues and systematic errors and to monitor accuracy and bias. They also enable laboratories to assess analytical performance in comparison with other laboratories that employ the same instrument or methods.
Developed by Randox Quality Control of Randox (Crumlin, United Kingdom), the eight new RIQAS (Randox International Quality Assessment Scheme) EQA programs are: CSF, Sweat Testing, Immunosuppressants, Trace Elements in Serum, Trace Elements in Urine, Trace Elements in Blood, Anti-TSH Receptor, and Cyfra 21-1. Cycles are scheduled to begin in March 2016.
The programs are available in liquid and lyophilized formats, covering the full clinical decision range, reassuring clinicians and patients that the laboratory is releasing accurate, reliable results. Monthly reporting supports rapid identification of errors and implementation of necessary corrective actions, thereby saving on expenses, resources, and valuable time by eliminating the need for patient sample retests. Randox QC’s rapid report turnaround will ensure that results are received within 24–72 hours. If required, corrective actions can then be implemented before the next cycle, providing more peace of mind.
RIQAS is the largest international EQA scheme, used by more than 32,000 laboratory participants in 123 countries. Such a large set of international peer groups provides increased confidence of the statistical validity of the extensive database of instrument and method results.
Related Links:
Randox
Randox Quality Control
RIQAS
Developed by Randox Quality Control of Randox (Crumlin, United Kingdom), the eight new RIQAS (Randox International Quality Assessment Scheme) EQA programs are: CSF, Sweat Testing, Immunosuppressants, Trace Elements in Serum, Trace Elements in Urine, Trace Elements in Blood, Anti-TSH Receptor, and Cyfra 21-1. Cycles are scheduled to begin in March 2016.
The programs are available in liquid and lyophilized formats, covering the full clinical decision range, reassuring clinicians and patients that the laboratory is releasing accurate, reliable results. Monthly reporting supports rapid identification of errors and implementation of necessary corrective actions, thereby saving on expenses, resources, and valuable time by eliminating the need for patient sample retests. Randox QC’s rapid report turnaround will ensure that results are received within 24–72 hours. If required, corrective actions can then be implemented before the next cycle, providing more peace of mind.
RIQAS is the largest international EQA scheme, used by more than 32,000 laboratory participants in 123 countries. Such a large set of international peer groups provides increased confidence of the statistical validity of the extensive database of instrument and method results.
Related Links:
Randox
Randox Quality Control
RIQAS
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms